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Abstract: Pharmacokinetic/pharmacodynamic (PK/PD) analysis has proved to be very useful
to establish rational dosage regimens of antimicrobial agents in human and veterinary medicine.
Actually, PK/PD studies are included in the European Medicines Agency (EMA) guidelines for the
evaluation of medicinal products. The PK/PD approach implies the use of in vitro, ex vivo, and
in vivo models, as well as mathematical models to describe the relationship between the kinetics
and the dynamic to determine the optimal dosing regimens of antimicrobials, but also to establish
susceptibility breakpoints, and prevention of resistance. The final goal is to optimize therapy in order
to maximize efficacy and minimize side effects and emergence of resistance. In this review, we revise
the PK/PD principles and the models to investigate the relationship between the PK and the PD of
antibiotics. Additionally, we highlight the outstanding role of the PK/PD analysis at different levels,
from the development and evaluation of new antibiotics to the optimization of the dosage regimens
of currently available drugs, both for human and animal use.
Keywords: antibiotic; pharmacokinetics; pharmacodynamics; antimicrobial resistance
1. Introduction
Antimicrobials—including antibiotics, antivirals, antifungals, and antiparasitics—are
essential medicines needed for a basic health-care system [1]. The World Health Organiza-
tion (WHO) has declared antimicrobial resistance (AMR) as one of the top 10 global public
health threats facing humanity. The AMR phenomenon is a serious and globally extended
challenge that occurs when bacteria, viruses, fungi, and parasites change over time and
no longer respond to medicines, threatening the effective prevention and treatment of an
ever-increasing range of infections [2].
AMR increases the risk of disease spread, severe illness, death, and it has a significant
economic impact, compromising not only the ability to treat infectious diseases, but also
impeding many other advances in the field of medicine. Misuse and overuse of antimicro-
bials are the main drivers in AMR development. In this context, WHO released the Access,
Watch, and Reserve (AWaRe) classification, which categorizes the antibiotics into different
stewardship groups to emphasize the importance of their appropriate use, with the aim of
supporting the development of tools for antibiotic management and to reduce bacterial
resistance [3]. Moreover, in May 2015, the World Health Assembly endorsed a global action
plan to face AMR, including antibiotic resistance, the most urgent drug resistance trend.
The optimization of the use of antimicrobial agents is one of the five strategic objectives set
out to achieve this goal [4]. This objective is especially relevant considering that in the last
10 years, no new group of antibiotics has been marketed in Europe [5].
AMR is a cross-cutting issue, and therefore, for achieving optimal health and well-
being outcomes it has to be tackled from a One Health perspective, recognizing the inter-
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connections between people, animals, plants, and their shared environment [6]. In this
sense, the coronavirus disease 2019 (COVID-19) pandemic had increased awareness of
the One Health approach to prevent the emergence of infectious diseases, strengthen the
need to proceed with this approach at all levels of academia, research, and governments
around the world [7]. Nowadays, the need for a One Health approach to address AMR is
supported internationally and included in the action plans of many countries [8].
Focusing on antibiotherapy, an ideal treatment optimization requires information on
the mechanisms involved in the effect of the antibiotics (pharmacodynamics, PD) and the
evolution of the antibiotic concentration in the patients (pharmacokinetics, PK). Different
models, including in vitro, ex vivo, and in vivo, have been developed to establish the
relationship between the PK and the PD of antimicrobials, and one of the main applications
is to design dosing strategies to enhance the probability of success of the antibiotic therapy,
as well as minimize the side effects and the emergence of resistances [9]. Moreover,
reminding that One Health aims to improve the assessment, treatment, and prevention of
disease in people and animals, the information obtained by applying PK/PD principles
can be applied reciprocally for the benefit of both, and the environment as well. On the
one hand, the use of animal models improves the predictability of preclinical studies used
for the development of medicines for human use. On the other hand, quantitative PK/PD
information obtained from clinical research can be useful in veterinary drug development.
As Schneider et al. describes, in reverse translational pharmacology, PK/PD modeling can
help in the selection of therapeutic candidates and the prediction of their optimal dosing
schedules (i.e., dose and frequency) both in humans and animals. In addition, this can be
done through extrapolation of disposition kinetics, efficacy, and safety data from/to spontaneous
animal models of the human disease pathophysiology to/from the clinic, because the knowledge
obtained from existing resources can be used one way or the other (from humans to animals
or vice versa) [10].
In this review, we present an overview of the PK/PD principles and the models to
evaluate the relationship between the PK and the PD of antibiotics, including breakpoints
establishment, susceptibility surveillance, therapeutic drug monitoring, and prediction
of resistances.
2. Pharmacokinetic/Pharmacodynamic Principles
The major indicator of the effect of the antibiotics (PD) is the minimum inhibitory
concentration (MIC), which provides information about the susceptibility of the pathogen
against the antibiotic [11]. However, the clinical outcome is conditioned not only by the
MIC value, it depends on the interactions among the host, the bacteria responsible for the
infection, and the administered antibiotic. The PK/PD analysis allows integrating and
analyzing jointly both the PK and PD information for drug use optimization.
The combination of pharmacokinetic and pharmacodynamic parameters can be de-
fined through the PK/PD indices. Depending on the activity pattern of the antibiotic,
three PK/PD indices have been established as the best descriptors of clinical efficacy and
bacterial kill characteristics of the antibiotic. The first pattern of antimicrobial activity
exhibits concentration-dependent activity and the PKPD indices preferred are the ratio
of the free-drug maximum concentration (f Cmax) to the MIC (f Cmax/MIC) or the area
under the free-drug concentration–time curve, typically over a 24-h period, to the MIC
(f AUC24/MIC). For the time-dependent pattern, the antibacterial effect is best described
by the percentage of time the free drug concentration remains above the MIC throughout
the dosing interval (f T>MIC). Finally, the best PK/PD ratio for concentration-dependent
with time-dependence antibiotics, is f AUC24/MIC [5,9,12,13]. The PK/PD indices have
also been related to suppression of emergence of resistance [14]. Table 1 summarizes the
PK/PD indices related to the efficacy of different antimicrobials.
Once the activity pattern is known, the magnitude of the index that is required for
antimicrobial efficacy should be established. This cut-off value, known as the pharmaco-
dynamic target (PDT), is the magnitude for a PK/PD index at which a desired level of
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predicted response is achieved. During the development of new antimicrobial agents, the
magnitude of the PK/PD index usually derives from studies in animals and/or in vitro
PD studies, although in more advanced stages of drug development, the results of clinical
PK/PD–response studies should be considered in conjunction with results from pre-clinical
PK/PD studies.
Table 1. PD indices related to the efficacy of different antimicrobials.














f Cmax/MIC: Free-drug maximum concentration to the MIC; f T>MIC: The percentage of time that the antimicrobial
free serum concentration remained above the MIC; f AUC24/MIC: The area under the free concentration-time
curve over 24 h divided by the MIC.
In the PK/PD analysis, the probability to reach the targeted exposure can be estimated
from the PK parameters of the antibiotic in a population. When the inter-patient variabil-
ity is included in the PK/PD analysis, the Monte Carlo simulation is a useful approach.
Monte Carlo methods are stochastic computational algorithms based on repeated random
sampling. To carry out the PK/PD analysis by Monte Carlo simulation, two elements are
needed: (i) A validated PK/PD model that provides the population PK parameters, the
inter-individual variability, and a covariate model that provides information of the influ-
ence of patient characteristics on the PK parameter, and (ii) the PD model that integrates
both the PK and PD parameters [9].
The probability that a specific value of the PK/PD index associated with the efficacy of
the antibiotic is achieved at a certain MIC is defined as the probability of target attainment
(PTA). The PTA corresponds to the percentage of simulated patients with an estimated
PK/PD index equal to or higher than the value related to the efficacy of the antibiotic
against a pathogen with a certain MIC. Potentially efficacious dose regimens must provide
a PTA > 90% [11,15]. The expected population PTA given a population of microorganisms
for a specific dosing regimen is named cumulative fraction of response (CFR) [16]. The
CFR can be considered as the expected probability of success of a dosing regimen against
bacteria in the absence of the specific value of MIC, and thus, the population distribution
of MICs is used.
3. Models to Study the PK/PD of Antimicrobials
To assure the quality of drugs, the European Medicines Agency (EMA) and its Commit-
tee for Medicinal Products for Human Use (CHMP) provide guidelines for the evaluation
of medicinal products, which in the area of antibacterial agents include microbiological
research, studies in animals, PK/PD investigations, and clinical trials [17,18]. The main
objective of PK/PD studies is to establish the relationship between the PK/PD indices,
and the clinical or the microbiological outcomes in patients, and one of the most impor-
tant applications is regimen selection for clinical studies [19]. Investigation in PK/PD of
antimicrobials can be considered as an iterative process through which in vitro and in vivo
experiments, population PK models, and in silico simulations are used to evaluate potential
dosing regimens and PK/PD targets. Each one displays strengths and weaknesses and
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may be regarded as complementary. The selection of the adequate analysis is critical for
the determination of the dosage regimens.
Preclinical models require robust indicators for antibacterial activity in humans, and
therefore, their results are very useful to optimize dose regimens for efficacy and prevention
of resistance [5]. The EMA guidelines on the use of the PK and PD in the development
of antimicrobial medicinal products [17] recommends testing about 4–5 organisms of the
major target species or organism groups. The organisms should be representative of those
most relevant to the intended clinical uses and should exhibit MICs of the test agent
that include values at the upper end of the wild-type distribution. The PK/PD model
methods fell into three categories: In vitro, ex vivo, and in vivo [20,21], and they must be
regarded as complementary. A description of these methods, with the main advantages
and disadvantages is included in this section.
3.1. In Vitro Models
Although the MIC is the major indicator of the effect of the antibiotics it only provides
approximate information about the antibacterial effect of the antibiotics [11]. In vitro
models go further than the simple assessment of the MIC of the antibiotic against a
certain microorganism. They provide detailed information about the magnitude and time
course of anti-infective activity in a controlled environment. However, they require a
more sophisticated data analysis to capture the observed kill curve profiles to allow for
translation. In vitro models may be used to [17]:
- Describe the PK/PD relationships for representative organisms and a range of inocula;
- Assess the effects of different PK profiles;
- Study the relationships between rates of emergent resistance, drug exposure, and
duration of therapy.
In vitro results generally correlate well with microbiological efficacy in humans if
there is a similar level of bacterial growth and exposure to the antimicrobial as it happens
at the in vivo site of infection [22]. However, despite the fact that in vitro studies may be
efficient, the translation of in vitro results to the clinic may be hampered. Some reasons are
related to the lack of in vivo physiological processes (for instance, the lack of a functioning
immune system) and others, since not all conditions for antibiotics and bacteria in vivo
may be known.
3.1.1. Static Assays
The simplest model for in vitro PK/PD studies consists of adding the antibiotic in
a constant concentration to the culture medium with a certain number of bacteria, and
evaluating the change in bacterial count at different times. This model can be useful to
assess the exposure-response relationship against the predominant bacterial population
of a single antibiotic, and to evaluate PD drug interactions of antibiotic combinations [20].
The concentration range of the antibiotic, the composition of the culture medium, and the
initial size of the bacterial inoculum are key factors [23]. The concentration range must
include an antibacterial agent’s concentration that does not kill any bacteria, as well as
a concentration that completely kills the bacteria. The culture medium must ensure the
growth of the bacteria, and accurately simulate the conditions in vivo. The most important
advantage of static models includes the simplicity, low cost, and minimal equipment
requirements. As main disadvantages, possible antibiotic degradation, constant exposition
of the bacteria to the antibiotic, and short duration of the experiments (typically 24–48 h)
can me mentioned [20].
3.1.2. Dynamic Assays
In the dynamic models, the concentration of the antimicrobial changes over time sim-
ulating the concentration versus time profile that happens in the patient [24]. They are clas-
sified into two categories depending on the number or compartments: One-compartment
Pharmaceutics 2021, 13, 833 5 of 27
and two-compartment models. There are also more specific models useful to evaluate
specific infections, such as the bladder infection models that will also be described below.
• One-compartment model
In this model, also named chemostat, the antimicrobial agent is added to a culture
bioreactor containing the bacterial inoculum, where the antibiotic is also administered [24].
The culture medium is continuously removed and replaced by a fresh medium to maintain
the total volume as constant (generally about 100–250 mL). The system can simulate the
time course of the antibiotic concentration as it occurs in vivo in a patient. Different ad-
ministration strategies may be assayed: Bolus, infusion or first order input. As in the static
model, the change in bacterial count at different times is measured. Experiments normally
last up to over 96 h, but frequently they are conducted in shorter times, over 24 h. Figure 1
represents the different modalities of the system depending on the administration type.
Figure 1. Dynamic one-compartment in vitro infection model (chemostat).
This model has shown to be useful in evaluating bacterial killing and regrowth with
antibiotics in monotherapy, and combinations as well. In a recent study, the efficacy of
ceftolozane-tazobactam in combination with colistin against extensively drug-resistant
Pseudomonas aeruginosa, including high-risk clones, was evaluated using the chemostat
system [25]. The authors observed an additive or synergistic interaction for ceftolozane
-tazobactam with colistin, and particularly against resistant strains. The chemostat system
has some limitations, including elimination of bacteria, contamination of the medium,
incomplete oxygenation, and accumulation of waste products over time [20].
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• Two-compartment model
In two-compartment PK/PD models, contrary to one-compartment ones, bacterial
washout is prevented by physically separating bacteria from the central reservoir within
a small peripheral compartment (typically 10–20 mL) [24]. The most common example
is the hollow fiber infection model (HFIM). The system consists of thousands of small
tubular fibers (filters) in a cartridge through which the medium is pumped from the central
reservoir. The wall of the fibers has pores that retain the microorganisms, but allows the free
diffusion of the antibiotic. Therefore, while the bacteria are entrapped in the extracapillary
space of the hollow fiber cartridge, the fresh medium and antibiotic diffuse through the
fiber wall to the extracapillary space (Figure 2).
Figure 2. Representation of the hollow fiber infection model (HFIM).
As with the chemostat, the HFIM allows simulation of a range of drug disposition
profiles and bacteria loads. A major advantage over other in vitro methods is that the
duration of the experiments is virtually unlimited [26], and durations up to several weeks
have been published for Mycobacterium tuberculosis [21,27]. As experiments may last
long periods, this method allows evaluating the relationship between drug exposure and
resistance development.
One of the most important limitations of HFIM is the high cost, mainly due to the
price of the cartridges. Another drawback is the binding of lipophilic antibiotics to the
components of the hollow fibers, although different materials are available to minimize
binding [20].
In order to design and work with one of these in the vitro model, it is important to
take into account a series of considerations covering the selection of the most adequate
strain, including reference strains, the initial bacterial inoculum, the duration of the therapy
and resistance prevention, the stability of the antimicrobial, the antibiotic concentration
profile. It is also important to have adequate methods to quantify the drug concentration
and bacterial populations [20].
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3.1.3. In Vitro PK/PD Bladder Infection Models
To investigate uncomplicated lower urinary tract infections (UTIs), normal urodynam-
ics must be considered. Experimental models must take into account dilution of bacteria
during bladder filling and loss through voiding. Over the past years, different models have
been developed [28]. In a recent study, a new multicompartment infection model applies a
continuous elimination into 16 bladder compartments [29]. This model has been used to
evaluate the oral fosfomycin treatment for enterococcal urinary tract infections. A next-
generation “micromodel” has been recently developed and it has been used to analyze the
impact of urinary flow on the persistence of E. coli colonization [30]. This dynamic in vitro
model used transitional epithelial cells and type IV collagen, and by simulating urinary
tract shear stresses and flow velocities, the dynamics of E. coli cell adhesion was studied.
Using this model, the authors reported a phenomenon of epithelial cell “rolling-shedding”
that promotes bacterial attachment into deeper layers of epithelial cells.
In vitro UTI models try to mimic as closely as possible the conditions at the site of
infection. However, an important drawback limits the translation to humans. For example,
although the urinary bladder contains relatively low oxygen (PO2 is about 40 mmHg),
in vitro models are generally run at normal atmospheric conditions [28].
3.2. Ex Vivo Models
PK/PD relationships can be studied using ex vivo models, such as the tissue cage
(TC) model. This model consists of perforated cylinder, tubes or spheres, implanted in
subcutaneous tissues. After implantation (3 to 4 weeks), the granulation tissue surrounds
and partially fills the cage, the remainder being filled with an interstitial fluid which can
be inflamed with carrageenan (to produce a sterile exudate), infected (inoculated septic
exudate) or not (transudate), allowing antimicrobial action to be monitored as a local,
isolated infection [21]. TCs are, actually, test tubes implanted into the animal, enabling
ethically accepted sequential sampling. The effect of the antibiotic can be directly assayed
by determining the concentration of the drug and its metabolites (active or inactive) and by
monitoring bacterial counts in the TC fluid. The ex vivo killing effect of the antimicrobials in
the collected fluid (transudate, inflammatory exudate) may be evaluated through time-kill
curve assays [31].
In a recent study, the potential synergistic interaction between tigecycline and amino-
glycosides against clinical isolates of carbapenem-resistant Klebsiella pneumoniae (CR-KP)
was assessed using a tissue-cage infection model of rats [32]. The study revealed that, com-
pared with single drugs, tigecycline combined with aminoglycosides could exert synergistic
effects and reduce the emergence of tigecycline resistance. Therefore, the study allowed
the conclusion that this combination might be an effective alternative when treating CR-KP
infections in clinical practice.
One advantage of the TC model is the presence of natural immunity. Moreover, it al-
lows detecting matrix-specific effects of drug action. For instance, thymidine concentration
in serum is high in cattle, rats, and mice, but low in dogs and man. This compound is a
known antagonist of the action of trimethoprim on some bacteria, such as E. coli. In a previ-
ous study using a TC model in calves, the authors unexpectedly did not detect the effect
of trimethoprim on E. coli, since the high levels of thymidine were enough to antagonize
the antibacterial effect of the antimicrobial [33]. These findings show the inconvenience of
extrapolating data from one species to the other.
3.3. In Vivo Animal Models
Various established infection animal models have been used for the experimental
antibacterial PK/PD evaluation. The advantage of the animal models is that they can
truly reflect the progress of drug and bacterial exposure in the animal model. The effect
of virulence, immune function, the injection of the test microorganism, and the antibiotic
concentration at the infection site are the main determining factors. The most impor-
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tant disadvantage of the in vivo models is that the drug concentration cannot be quickly
measured [23].
Zhao et al. [34] have reviewed animal infection models that have been extensively
used in antibiotic discovery and development, including PK/PD analyses. These models
involve the inoculation to the animal of a certain number of bacteria. In general, mice and
rats are the preferred experimental animals due to their low cost and ease of handling.
To induce the infection, virulent bacterial strains are used, and to produce a progressive
infection, high inoculums, immunocompromised animals, and/or adjuvants (formalin or
mucin) may be required. The primary end-points is the reduction of bacterial burden in
the infected tissue (expressed as colony-forming units (CFU)), which is typically assessed
at 24 h after initiation of the antimicrobial therapy. According to the CHMP guidelines,
pathogen specific PK/PD targets resulting in a net stasis, a 1-log10, and 2-log10 reduction
of CFU must be provided [15].
The most relevant animal models of PK/PD studies are the murine thigh and lung
infections. Others include skin and soft tissue infections, septicemia, meningitis, urinary
tract infections, endocarditis or intraperitoneal infections [34]. In most studies, neutropenia
is induced with cyclophoshamide to minimize the effect of the immune system as a
confounder. Models of infection for specific microorganisms have also been reported. For
example, a recent publication describes in vivo mouse models of both local and systemic
Staphylococcus aureus infection, and presents protocols for models of subcutaneous infection,
tape stripping skin infection, sample collection to determine skin structure, production
of inflammatory mediators, and bacterial load, post-traumatic osteomyelitis model, and
intravenous infection of the retro-orbital sinus [35].
In the thigh infection model, an inoculum of 105−8 CFU of a certain pathogen is
injected intra-muscularly, and after therapy with the antibiotic, the animal is euthanized.
The homogenized tissue and the reduction in bacterial burden in the mice’s thighs indicates
the efficacy [34]. This model is generally used in the development of new antibiotics, and it
has been shown to be helpful for predicting efficacy for a number of indications, including
pneumonia, skin and soft tissue infections, intra-abdominal infections or septicemia [34].
One advantage is that the two thighs of the animals can be used, allowing a reduction in
the number of animals per experiment.
Among others, lung infection models include those that mimic human pneumonia [36].
Pneumonia can be induced in the animals by different methods: Exposure to aerosol,
transtracheal injection, peroral intubation or intranasal inoculation, and each has specific
strengths and weaknesses. In a recent study, to evaluate the effect of omadacycline against S.
aureus, neutropenic mice were infected by the intranasal route. Two hours after inoculation
into lungs, the mice were treated with the antimicrobial by the subcutaneous route, and 24-
h later, the animals were sacrificed and the burden of organisms was enumerated from lung
homogenates. The dose-response curves revealed the potent in vivo effect of omadacycline
against 10 MSSA (methicillin-susceptible S. aureus)/MRSA (methicillin-resistant S. aureus)
strains [37].
Biofilm-related animal models have also been developed with or without the addition
of foreign material, including central venous catheter models, subcutaneous foreign body
infection models, and osteomyelitis infection models. The microorganisms inoculated
are usually planktonic but capable of attaching to surfaces and developing biofilm [38].
Dalton et al. [39] developed an in vivo polymicrobial biofilm wound infection model to
study interspecies interactions in biofilms and their relation to wound chronicity.
For real-time monitoring of infections, animal models using luminescent bacteria have
been developed. These models allow following the course of infection in live animals
in a non-invasive manner. However, as compared with viable counting methods, the
sensitivity of bioluminescence is generally lower. Consequently, they are not useful to
evaluate compounds with mild antibacterial effect [40].
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4. PK/PD Modeling of Microbial Kill-Curves
Mathematical modeling to analyze PK/PD data resulting from in vitro, ex vivo or
in vivo studies has an important impact on the development and optimization of antibiotic
dosing. The complexity of the PK/PD models depends on the type of data generated
from the experiments. The kill-curves, where a time course of drug-bacterial response is
produced, have been used to describe bacterial growth and death rates, drug effects, and
the emergence of resistant strains within a population [41]. An example of a time kill-curve
profile is shown in Figure 3.
Figure 3. Example of a time-kill curve. The blue line shows the evolution of the initial inoculum in
the absence of antibiotic (control); the green line represents the reduction in the bacterial count in the
presence of antibiotic (killing effect); the red line explains the behavior in the bacterial load when a
regrowth effect appears.
4.1. MIC-Based Approach
Classification of antibiotics into time-dependent versus concentration-dependent
killing has guided the dosing of antimicrobials for many years. This was achieved through
relating drug exposure to the minimum inhibition concentration (MIC). The estimation
of the best PK/PD index of a certain microorganism is calculated by plotting the value of
an efficacy endpoint (typically log10 CFU/mL after 24 h) versus the magnitude of each of
the three PK/PD indices [42] (Figure 4). Although the application of MIC-based PK/PD
indices may be useful for optimization of dosing regiments, it is actually, a simplification
of the PK/PD relationship.
4.2. Mechanism-Based Models
To analyze the PK/PD data, mechanism-based models can be applied. These models
consider the two most important factors that determine how effective a treatment will be
for a given patient: The free and available antibiotic concentration at the infection site (PK),
and the susceptibility of the bacteria (PD) [43]. These models describe the time course of
drug effects and disease, and implement the mechanism of action of the antimicrobial or the
mechanism of resistance, thereby maximizing the information gained from experimental
data. They can simultaneously describe and predict the time course of bacterial killing
and resistant emergence and can be applied to evaluate the effect of antimicrobials in
monotherapy and in combination [20].
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Figure 4. Relationship between the AUC and the number of colony-forming units (CUF). The dotted
line indicates the initial inoculum.
The mechanistic models consider several parameters rather than the simple MIC value.
They usually include, at minimum, a control growth rate constant (Kgrowth) and a killing
rate Kdeath), a maximum kill rate (Emax) and a potency value such as the half-maximum
effect concentration (EC50) [44]. Some authors have shown a relationship between the MIC
and the EC50 for a certain antibiotic/bacteria combination [45]. However, since the MIC is
defined by the absence of visible growth at a certain time point, it is not conditioned by
the maximum kill rate, and therefore, provides less information. In fact, similar values of
MIC can be obtained with different growth and kill rates [44]. Over time, mathematical
models that describe the microbial kill-curves have become more detailed and sophisticated.
For instance, more complicated models include delay functions or factors to evaluate the
combination of antibiotics [46]. The Figure 5 shows a schematic representation of a model
used to characterize the aztreonam-avibactam killing effect on drug susceptible and less-
susceptible bacteria, designed from data obtained with a static-kill model [47].
Figure 5. Schematic representation of a model used to characterize the aztreonam-avibactam killing
effect on drug susceptible (P1) and less susceptible (P2) bacteria. Adapted from [47]; Published by
the American Society for Clinical Pharmacology and Therapeutics, 2019.
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5. Application of PK/PD Analysis and Population Pharmacokinetics for the
Development and Optimization of Antimicrobial Treatments
PK/PD modeling implies the use of mathematical equations to express drug-related
biological changes, what makes it a useful tool to describe the kinetic and dynamic relation
for new drugs, to determine the optimal dosing regimens, but also to establish susceptibility
breakpoints, and to optimize pre-existing dosing regimens with direct application on
clinical situations and in veterinary medicine [9].
5.1. PK/PD Analysis in Drug Development
The application of PK/PD principles is a powerful tool to elucidate the clinical po-
tential of antimicrobial agents in early stages of development [48]. Nowadays, different
sources of PK/PD data are integrated during the drug development procedure, which
provide a stronger evidence to support the approval of new antimicrobials [49]. Animal
PK/PD studies and in vitro models have relevant influence on indications and recommen-
dation of dosing regimens. Additionally, thanks to preclinical PK/PD studies, smaller
sample sizes may be used in clinical trials [5]. As a result, both the EMA and the FDA
consider PK/PD experiments and simulations as a key step in the development process of
antimicrobial agents [5,15,17,18,49,50]. Actually, data from in vitro and animal infection
models are required for entering first-in-human studies, and after clinical development,
to obtain market approval by the two regulatory agencies. For instance, for the approval
of dalbavancin, the in vivo PK/PD relationship for Staphylococcus aureus was investigated
using a neutropenic model of animal infection that showed that net reduction in the log10
of colony-forming units was greatest when larger doses were given less frequently [51].
One of the main challenges of the development of an antimicrobial drug is to deter-
mine the correlation between in vitro susceptibility and clinical efficacy. An integrated
model-based approach plays a relevant role in drug development and evaluation, since it
enables an informed decision-making process at the preclinical and clinical development
stages [52]. As discussed above, validated in vitro PK/PD and animal infection models
have been extensively used for identifying the most predictive PK/PD indices, offering
a support to optimize study designs in terms of minimizing the cost and duration of
clinical trials, increasing the success rates, and accelerating the drug development pro-
cess. These preclinical PK/PD models are a key point in the search for new antimicrobial
treatments [24].
The use of PK/PD analysis has led to a reduction or sometimes, to a replacement of
clinical dose-finding studies during the clinical development of new antimicrobial agents.
The EMA defends that the PTA can be used to predict whether a treatment may be useful
against specific microorganisms, and underlines the relevance of this fact for infections
caused by multi-resistant and rare bacteria, since very few are likely to have been treated in
pre-licensure clinical studies and it may be very difficult to interpret the clinical outcome data [15].
In any case, after the preclinical evaluations, the human PK information is critical for
the selection of potentially effective dose regimens. Population PK models have to be de-
veloped in order to predict human exposures to the drug and to explore exposure-response
relationships in the target population [15]. The population PK approach during drug
development allows integrating information of pharmacokinetics from sparse, dense or a
combination of sparse and dense data. The results obtained from data-rich Phase I studies,
can be used to establish or optimize PK and PK/PD models and to quantify for the first
time the variability in humans [52]. From these early phases until drug commercialization,
the model based drug development allows using knowledge at every stage, integrating
all the information, which makes it possible to refine the models iteratively and optimize
decision making.
In order to obtain reliable results evaluating dosing regimens, the development of
population PK models is imperative. The use of population approach has been one of the
major developments in pharmacometrics. Population PK models help define the sources
and correlates of pharmacokinetic variability in target patient populations and their impact
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upon drug disposition [53]. The main objective of population PK models is to determine
the mean values of PK parameters (i.e., clearance, volume of distribution), inter-individual
variability, intra-individual variability, and between-occasion variability, and to account for
explanatory covariates of interest [54]. Population PK allows identifying demographical,
physio-pathological, therapeutical or other features that vary between subjects, and that
could be responsible for some of the differences in the achieved drug concentrations.
A large evolution in the field of data analysis for drug development has been ob-
served and, concurrently, the terminology has also evolved. The term Model Informed
Drug Discovery and Development (MiD3) was firstly defined in 2016 [55] as quantitative
framework for prediction and extrapolation, centered on knowledge and inference generated from
integrated models of compound, mechanism and disease level data and aimed at improving the
quality, efficiency and cost effectiveness of decision making. The MiD3 workgroup considers
this as a holistic term to term to characterize a variety of quantitative approaches used to improve
the quality, efficiency, and cost-effectiveness of decision making through “fit-for-purpose” data
analysis and prediction. Figure 6 depicts the evolution in the approaches and terminology
in this field. These approaches have a long history in the field of infectious diseases and
their application is closely linked to antimicrobial drug development [44]. Antimicrobial
agents’ development will require the integration and connection of different approaches
and the use of translational tools to support decision making. Moreover, Rayner et al.
in a recent review suggest the incorporation of deep learning and artificial intelligence
approaches [44].
Figure 6. Terminology used for quantitative approaches for data analysis. Adapted from [55];
Published by the American Society for Clinical Pharmacology and Therapeutics, 2016.
During drug development, the PK/PD analysis can also help in the design of the
dosage forms, since they strongly determine the efficacy of antimicrobial agents. For in-
stance, the PK/PD targets in antibiotics with time-dependent activity and short half-life,
such as beta-lactams, could be addressed with controlled-release dosage forms. In 2004, the
pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) twice daily formu-
lation demonstrated higher T>MIC values and was more effective than immediate release
formulations, achieving substantially better eradication rates against S. pneumoniae isolates
with MICs commonly encountered in the clinic [56]. More recently, Li et al. [57] evaluated
a three-pulse release tablet for amoxicillin using a physiologically based pharmacokinetic
modeling (PBPK) and they also concluded that their formulation extended the effective
plasma concentration compared to the immediate release tablet. In veterinary medicine,
with the same aim, Horwitz et al. developed a novel gastroretentive controlled-release
drug delivery system for amoxicillin therapy [58].
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More extensively, the application of biopharmaceutical pharmacometrics (BPMX)—i.e.,
pharmacometric modeling incorporating biopharmaceutical principles has been demon-
strated as a valuable tool in drug discovery and development. For instance, Sou et al. [59]
reported the application of BPMX for the PK analysis of three investigational antimicrobial
agents following pulmonary administration of different suspension formulations. They
developed a PK model considering formulation properties and provided a mechanism
to estimate dissolved drug concentrations in the lungs. The model was able to predict
that these antibiotics for lung delivery should ideally be delivered in a sustained release
formulation with high solubility for maximum local exposure in lungs for efficacy, with
rapid systemic clearance in plasma for reduced risk of unwanted systemic adverse effects.
5.2. PK/PD Analysis in Setting Susceptibility Breakpoints
An antimicrobial breakpoint is an established concentration value which essentially
defines at what value a microorganism is considered susceptible, intermediate or resistant
to antimicrobial therapy, and therefore is used to guide clinicians on the prescription of
antimicrobial drugs in the clinical practice [9,60]. The PK/PD analysis and Monte Carlo
simulations provide a useful platform for the establishment of breakpoints based on the
likelihood of obtaining a targeted exposure [61–63]. In the early 2000s, different studies
started, applying PK/PD simulations in the establishment of antimicrobial breakpoints
and comparing the results with The Clinical and Laboratory Standards Institute (CLSI)
and European Committee on Antimicrobial Susceptibility Testing (EUCAST) breakpoints
in force at the time [61,64–66]. More recently, the PK/PD criteria have been used to eval-
uate the susceptibility breakpoints of multidrug resistant bacteria such as Mycobacterium
tuberculosis [67,68]. Table 2 includes several examples of published studies that review
breakpoints by applying the PK/PD criteria.
Both EUCAST and CLSI have developed tools to apply the PK/PD analysis to set
and revise breakpoints. The EUCAST approach about the role of PK/PD in setting clinical
MIC breakpoints was reported in 2012 (Figure 7). Contrary to clinical breakpoints, PK/PD
breakpoints are regimen-dependent (species-independent) and therefore, different PK/PD
breakpoints can be obtained for the same drug [60]. Moreover, due to the increase of PK/PD
knowledge in this field, recently, CLSI defined a “susceptible dose-dependent (SDD)”
category for certain drug and organism combinations. In the same way, EUCAST proposed
a new definition for the intermediate category (I): “Susceptible, increased exposure (I)”.
CLSI defines the SDD category as a breakpoint that implies that the susceptibility of an
isolate depends on the dosing regimen that is used in the patient. For isolates that are in
the SDD category, it is necessary to move to a dosing regimen (i.e., higher doses, more
frequent doses or both) that results in higher drug exposure than that achieved with
the dose that was used to establish the susceptible breakpoint [69]. EUCAST considers
a microorganism as “Susceptible, increased exposure” when there is a high likelihood
of therapeutic success when exposure to the agent is increased by adjusting the dosing
regimen. Exposure depends on the dosage regimen (route of administration, dose, dosing
interval, infusion time), as well as distribution and excretion of the antimicrobial agent,
since they condition the drug concentration at the site of infection [15].
5.3. PK/PD Analysis as A Tool For Surveillance of Antibacterial Activity
The development and establishment of programs of integrated epidemiologic surveil-
lance on antimicrobial activity is essential to determine risk factors, to identify temporal
trends in resistance patterns, and to guide the clinician towards appropriate empiric treat-
ments [70]. Antimicrobial stewardship programs are needed to choose the treatment
properly in terms of optimal choice of drug, dosage, and duration of treatment, which leads
to a reduction of treatment-related costs, an improvement in clinical outcomes and safety,
and a reduction or a stabilization of antimicrobial resistance [71–74]. Standard surveillance
indices, based on MIC values, can be useful but they are not enough to detect changes
on the whole activity of antimicrobial agents, since some less evident variations in MIC
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distribution could lead to a loss of treatment efficacy [71,75]. The PK/PD analysis has
proved to be a useful tool to establish empirical antimicrobial therapy recommendations,
since it allows evaluating the overall activity of antimicrobial treatments by predicting the
probability of success for a treatment, incorporating the variability of the pharmacokinetic
parameters and the bacterial population MIC distribution (local MIC distributions).
Table 2. Published studies that review breakpoints by applying the PK/PD criteria.
Reference Bacteria Antimicrobials
Betalactams Others




























































Zuur et al. [68] Mycobacterium tuberculosis Isoniazid
Pyrazinamide
Rifampin
Deshpande et al. [67] Mycobacterium tuberculosis Levofloxacin
Accordingly, during the last years, the Survey of Antibiotic Resistance (SOAR) has
published periodically the survey results of Antibiotic Resistance in different countries
to provide a picture of the state of antibiotic susceptibility of different pathogens. The
Survey of Antibiotic Resistance (SOAR) is an international antibiotic resistance surveillance
study that focuses on key respiratory pathogens from community-acquired infections
and has been running since 2002 in the Middle East, Africa, Latin America, Asia-Pacific
countries, and Commonwealth of Independent States countries. It analyzes data based
on CLSI, EUCAST (dose-specific), and PK/PD breakpoints [76–96]. The study concluded
that there are large country-specific differences in antibiotic susceptibility even within the
same region and reinforced the need for regular antibiotic resistance surveillance in order
to track susceptibility changes over time.
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Figure 7. Process of setting PK/PD breakpoints by EUCAST. Adapted with permission from [60];
Published by Elsevier, 2012.
Additionally, many publications include the PK/PD analysis as a key point for the
treatment optimization and surveillance of antibacterial activity. As an example, different
studies about P. aeruginosa isolates conclude that susceptibility rates and the probabil-
ity of treatment success estimated by the PK/PD analysis are complementary tools for
surveillance purposes and both should be considered together when making decisions
to guide antimicrobial therapy [71,72,75]. A recently published review about treatment
optimization for sexually transmitted infections also highlights the urgent needs of sys-
tematic PK/PD evaluation to ensure resistance suppression and bacterial eradication at
all sites of infection [97]. Finally, the PK/PD analysis has also been demonstrated to be
useful in identifying changes in antimicrobial activity after the implantation of vaccination
programs, since complementary information to the susceptibility rates or the MIC values is
provided [98,99]. Regular epidemiologic surveillance programs have an important role to
guide the clinician towards appropriate empiric treatments and they should incorporate
the local ecology to provide a personalized approach. In this regard, the monitorization
of the CFR values, allows estimating the probability of success for a treatment without
knowledge of the susceptibility of the specific isolate responsible for the infection, but
taking into account the MIC distribution of a particular institution or hospital wards or
regions/countries.
5.4. Population PK and PK/PD to Optimize Dosing Regimens. Therapeutic Drug
Monitoring (TDM)
Many efforts have been made along the last years in order to improve the use of antimi-
crobials and to reverse AMR. Consequently, different strategies have been implemented
in hospital care to optimize the antimicrobial dosing regimens [100] and in this field, the
use of PK/PD analysis has become an essential tool to be included in antimicrobial stew-
ardship programs [54]. Moreover, the Guidelines for Developing an Institutional Program
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to Enhance Antimicrobial Stewardship published by the Infectious Diseases Society of
America, and the Society for Healthcare Epidemiology of America, in 2007 already stated
that the optimization of antimicrobial dosing based on individual patient characteristics, causative
organism, site of infection, and pharmacokinetic and pharmacodynamic characteristics of the drug is
an important part of antimicrobial stewardship [101].
The integration of basic PK/PD relationship, defined from in vitro and animal models,
with human PK studies by mathematical modeling and simulation that considers patient
variability creates a powerful tool to inform dosing strategies. The statistical method most
often used is Monte Carlo simulations (MCS), but other methods may be used. Monte Carlo
simulation can be performed using basic PK data which considers mean PK parameter
values and variability. However, the better approach to perform Monte Carlo simulation
requires: (i) A validated population PK model including the structural model (providing
population PK parameters), a variability model (providing inter-individual variability), and
a covariate model (studying the influence of patient characteristics on the PK parameters)
and (ii) a PD model where the interrelationship of the PK and PD parameters has been
studied [9]. Whenever possible, the PK data for simulations should be based on population
PK models built from or including PK data from the infected target patient population, with
an assessment of the effect of covariates [15]. Using simulations, it is possible to estimate the
probability of attaining the target (PTA) over a range of CMI, and the cumulative fraction
of response (CFR) when a MIC distribution is available (useful for empiric treatment).
The population PK analysis is a well-accepted approach not only to optimize dosing
regimens during new drug developments, but also to improve dosing regimens of old
antibiotics and to individualize the antimicrobial treatment in the clinical setting [54].
In fact, optimization of the clinical use of old drugs is of main concern and must be
as prioritized as the determination of the therapeutic role of new antibiotics [102]. The
covariate analysis in population PK modeling allows evaluating the impact of clinical or
demographic parameters on the exposure to the drug and helps in elucidating whether
dose adjustments are needed in specific populations. As an example, obese patients,
pregnant women, pediatric patients, patients with renal or hepatic impairment or critically
ill patients are at high risk of treatment failure or toxicity, as a consequence of physiological
or pathological changes that often result in changes in the PK behavior and achievement of
PK/PD targets [49]. Antimicrobial dosing in these populations is complex and remains a
challenge. Therefore, robust population PK models have to be developed including data
from target patient populations with the target indication and considering the adequate
PK/PD target.
The physiologically based pharmacokinetic (PBPK) approach is increasingly being
used to provide information about drug disposition and exposure in specific subpopula-
tions or clinical situations or to evaluate drug-drug interactions. However, it is essential to
keep in mind that PBPK models are based on estimations of some physiological parameters
such as blood flow, which can be strongly different in special populations. Therefore,
it should be noted that this approach requires robust physiological and PK data in the
patient population [49]. Table 3 lists some research works that apply the PBPK approach to
optimize antimicrobial use in special populations. These studies show the usefulness of
PBPK for prediction of concentrations in different groups of patients, and ultimately for
dose individualization in different subgroups of patients.
Table 3. PBPK models developed with antimicrobial drugs in special populations.
Reference Patient Population Antimicrobial Route of Administration
Balbas-Martinez et al. [103] Children with complicatedurinary tract infection Ciprofloxacin Oral/intravenous
Schlender et al. [104] Pediatric/adult/geriatric Ciprofloxacin Oral/intravenous
Montanha et al. [105] Bariatric patients Amoxicillin Oral tablet/suspension
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Table 3. Cont.
Reference Patient Population Antimicrobial Route of Administration
Thémans et al. [106] Critical/non critical/obese Meropenem Intravenous
Cordes et al. [107] Patients with tuberculosis Isoniazid Oral
Hornik et al. [108] Pediatric Clindamycin Intravenous
Rimmler et al. [109] Perioperative patients Cefuroxime Intravenous
Joyner et al. [110] Patients with different bodymass indexes Ertapenem Intravenous
Tod et al. [111]
Patients with hemorrhagic
shock followed by fluid
resuscitation
Amoxicillin-clavulanate Intravenous
All in all, the PK modeling methods have been applied to design rational regimens for
administration of new and old antibiotics. Population PK models can be used to simulate
multiple dosing regimens and to predict the probability of target attainment in different
populations. As an example, PK/PD principles have been applied to defend the use of
extended and continuous infusion rather than short infusions of beta-lactams in septic
or critically ill patients [9,112–117]. Beta-lactams exhibit a time-dependent antibacterial
activity and therefore extending the duration of perfusion increases the probability to attain
the PK/PD target. Recently, continuous infusions have also been proposed to optimize the
treatment with linezolid in critically ill patients, especially those with augmented renal
clearance [118,119]. For antibiotics with concentration-dependent activity, other authors
recommend the daily dose once a day rather than lower doses more times a day, which
may reduce drug toxicity [120–122].
However, given the high inter-individual variability in certain circumstances where
antimicrobial PK is significantly altered (i.e., critically ill, patient with augmented renal
clearance, elderly, pregnant women or subjects with extreme body mass index), therapeutic
drug monitoring (TDM) may be indicated [123]. TDM is used to individualize dosing with
the aim of maximizing the probability of attaining therapeutic success and minimizing
the probability of toxicity and development of antimicrobial resistance [124]. Initially, the
purpose of TDM was limited to molecules with a narrow therapeutic range such as amino-
glycosides or glycopeptides, but it is extending its use to other drugs in specific subgroups
of patients or in situations where the bacteria responsible for the infections shows a limited
susceptibility to antimicrobial treatments. For instance, although TDM with beta-lactams
has not been extensively applied due to their wide therapeutic window, TDM can be useful
in relevant populations such as critically ill, obese, burns, neutropenic patients or subjects
with renal disease, since it allows determining the dosing regimen that maximizes the
probability to attain the PK/PD target and improve clinical outcome [115,124].
Antimicrobial stewardship has been defined as coordinated efforts to ensure that
patients receive the right antimicrobial agent, at the right dose, and for the right duration
while minimizing adverse drug events and antimicrobial resistance [125]. The first guide-
lines for conducting antimicrobial stewardship in the hospitalized setting were published
in 2007. These guidelines recommend that the stewardship program employs PK/PD prin-
ciples as well as adopts computerized decision support technologies when possible [98].
In fact, the Infectious Diseases Society of America (IDSA) and the Society for Healthcare
Epidemiology of America (SHE) guidelines on antimicrobial stewardship recommend the
use of PK/PD dose optimization, as well as the adoption of computer decision supports
(CDS) when possible [126].
Despite the relevance of PK/PD modeling and simulation programs, they are generally
absent in clinical practice for TDM. To facilitate the application of PK/PD in clinical routine,
different technologies have been developed. These tools may be specifically used to assist
antimicrobial treatment selection and/or dosing regimen design using PK/PD principles
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and/or Bayesian modeling. Some examples are PK/PD compass (http://www.pkpdcompass.
com/, accessed on 1 June 2021), TDMx (http://www.tdmx.eu, Accessed on 1 June 2021),
DoseMERx (http://doseme-rx.com, accessed on 1 June 2021), InsightRx (http://insight-rx.
com, accessed on 1 June 2021), AMKnom (http://shiny.cumulo.usal.es/amknom/, accessed
on 1 June 2021), and MeroRisk Calculator (https://www.bcp.fu-berlin.de/en/pharmazie/
faecher/klinische_pharmazie/arbeitsgruppe_kloft/forschung/MRc/index.html, accessed
on 1 June 2021). These technologies, web or mobile-based, use population PK models and
Monte Carlo simulations to perform the PK/PD target attainment analysis and inform dosing
regimens of a variety of antibiotics [98].
5.5. Application of PK/PD Modeling to Drug Resistance Prediction
Antimicrobial resistance is an ecological problem that affects the health of humans,
animals, and the environment [8]. Taking into account the great threat that the AMR
is and the scarce number of new antibiotics, the optimization of the use of currently
available antibacterial agents should also consider the minimization of emergence of
resistant mutants. The selection of dosage regimens with the aim to suppress resistance
can also be guided by the PK/PD criteria. PK/PD targets required to attain this objective
have been described in the in vitro and pre-clinical in vivo studies.
The PK/PD indices related to suppression of emergence of resistance include the
conventional PK/PD ratios explained in point 2 but additionally, different works suggest
that they should be based on the mutant prevention concentration (MPC). The MPC has
been defined as the MIC of the least susceptible single-step mutant. When the antibiotic
concentration exceeds the MPC, the cell growth requires an organism to have developed
two or more resistance-causing spontaneous chromosomal point mutations [127–129]. The
concentration range between MIC and MPC is known as the mutant selection window
(MSW) (Figure 8), and the selection of resistant bacterial subpopulations is promoted when
concentrations are maintained inside this range.
Figure 8. Effect of exposure to the increasing antibiotic concentration on the burden of resistant
and susceptible bacterial populations. CFU: Colony-forming units; MIC: Minimum inhibitory
concentration; MPC: Mutant prevention concentration; MSW: Mutation selection window.
Unfortunately, the target exposures required to reduce the development of resistance
are not well defined in many cases. Sumi et al. [14] published in 2019 a systematic review
with the aim to describe the currently known antibiotic PK/PD indices required to suppress
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the emergence of Gram-negative bacterial antibiotic resistance, but further research would
be welcome.
Analyzing the available information, the first conclusion is that the exposure required
is usually much higher than that to assess the treatment efficacy and therefore, standard
dosing regimens are too low to reach the established targets to prevent the emergence of
resistance mechanisms [130]. Moreover, the benefits of implementing the high PK/PD
targets needed to avoid resistance must be balanced with the potential risks of toxicity.
Consequently, the use of alternative dosing strategies, such as the extended or continuous
infusions should be considered to enhance the probability of reaching the targeted PK/PD
indices for suppression of resistance [14].
5.6. Application of PK/PD Modeling in Veterinary Medicine
Antimicrobial agents are the most frequently used drugs in veterinary medicine [23],
being the antimicrobial consumption by animals is twice than that used by humans [131].
There is no doubt about their usefulness to prevent disease and to promote growth in food
animals, providing healthy animal-source food [132]. However, the abuse and the misuse
of antimicrobials in veterinary medicine have led to higher rates of treatment failure and
to the development and dissemination of bacterial resistance [23]. Therefore, all efforts
have to be undertaken to reduce the consumption of antimicrobials in veterinary and to
use them reasonably, and the same principles deserve to be applied in veterinary medicine
as well as in human medicine. At this point, PK/PD modeling is an important tool that
undoubtedly helps in optimizing the dosing regimens of antimicrobial agents used in
veterinary medicine [23,133].
The PK/PD approach was firstly applied in veterinary medicine in the 1990s [21,134,135].
Since then, many research studies have been published PK/PD in the veterinary field. As an
example, Table 4 resumes the papers published during the last 5 years. As for humans, in vitro,
in vivo, and ex vivo studies are necessary to evaluate antimicrobial drugs for veterinary use.
Table 4. Published articles about PK/PD modeling in veterinary medicine.
Reference Year Antimicrobial Study Description
Burch et al. [136] 2018 Amoxicillin Review the PK and PD in pigs
El Badawy et al. [137] 2019 Cefquinome PK and PD in lactating goats
Lei et al. [138] 2018 Piscidin Evaluation of an antimicrobial peptide in a ratanimal model for a future use in veterinary medicine
Vercelli et al. [139] 2020 Levofloxacin PK/PD of levofloxacin in non-lactating goats
Birhanu et al. [140] 2020 Marbofloxacin in combinationwith methyl gallate
PK/PD analysis of marbofloxacin in combination
with methyl gallate in a rat animal model
Li et al. [141] 2020 Colistin in Combination WithGamithromycin
In vitro susceptibility and time-kill tests and in vivo
PK and PD assays using a neutropenic murine lung
infection model
Zeng et al. [142] 2018 Tildipirosin PK/PD modeling in a murine lung infection model
Maan et al. [143] 2020 Aditoprim In vivo intrauterine PK in cattles and in vitro and exvivo PD
Huang et al. [144] 2019 Tilmicosin PK/PD analysis in an in vitro dynamic model
Fernández-Varón et al. [145] 2016 Ceftiofur PK in lactating goats, in vitro and ex vivo activity,and determination of PK/PD index
Yang et al. [146] 2021 Danofloxacin PK in piglet and PK/PD analysis in vivo and ex vivo
Yu et al. [147] 2017 Sarafloxacin PK/PD in Muscovy ducks
Cazer et al. [148] 2017 Chlortetracycline PK/PD and the enteric bacterial populationdynamics in beef cattle
In 2002, and in accordance with the existing evidence, the EMA Committee for Medici-
nal Products for Veterinary Use (CVMP) established in their guideline for the demonstration
of efficacy for veterinary medicinal products containing antimicrobial substances, that the
PK/PD analysis should be carried out in order to select an appropriate strategy of adminis-
tration, to optimize dosage, to achieve optimal efficacy, and to minimize the development
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of resistance [149]. However, in 2004, Lees et al. [21,150] proposed the introduction of the
PK/PD approach to setting dosing regimens for veterinary antimicrobials. Later, in 2016,
EMA updated the CVMP guideline for the demonstration of efficacy for veterinary medici-
nal products containing antimicrobial substances to introduce PK/PD studies for dosing
selection and to establish breakpoints [151]. Moreover, the application of the EUCAST ap-
proach and Monte Carlo simulation to support the selection of a clinical breakpoint is also
acceptable. Recently, the CVMP has published the reflection paper on dose optimization of
established veterinary antibiotics in the context of a summary of product characteristics
harmonization [152], which defends the importance of revising the dosing regimens of
older antibiotics due to the risk to increase antimicrobial resistance rates as a consequence
of inappropriate exposure. PK/PD modeling should be the tool for decision-making and
both the PK and PD variability should be taken into account.
In essence, the application of PK/PD principles in veterinary medicine is widely
accepted, although further research is required for a better understanding of the PK/PD
relationships of veterinary drugs. New modeling approaches should contribute to im-
prove the antimicrobial use in animals with the aim to avoid unnecessary exposure to
antimicrobials, to ensure the efficacy of the treatment, and also to prevent the selection of
resistant bacteria.
6. Conclusions
In conclusion, this review outlines the current state of the art of the PK/PD analysis
in the development and evaluation of antimicrobials. Regulatory guidelines include the
PK/PD approach to advance in effective drug development and regulatory evaluation,
not only in human medicine but also in veterinary. Different in vitro, ex vivo, and in vivo
methods have been developed to establish the relationship between the PK/PD indices and
the clinical or the microbiological outcomes in patients. We highlight the relevant role of this
approach in the optimization of existing and new antibiotics, and also in the determination
of susceptibility breakpoints and in surveillance programs. Despite the important progress
of PK/PD in the last years, some limitations are still present. Thus, additional work is
necessary to improve the quality and external validation of in vitro and in vivo studies,
and new standardized methodological approaches must be developed. Optimizing the
available translational PK/PD tools is also very important to predict successful treatment
regimens, and to prevent the development of multi-drug resistant bacteria. In this sense, an
important challenge of PK/PD is the application in clinical practice for dose optimization
and to prevent the development of multi-drug resistant bacteria. Nevertheless, we have
to keep in mind that PK/PD modeling and simulation is continuously evolving and new
methods are appearing. In fact, several challenges are needed to be further addressed, such
as the management of antibiotic combinations, the relationship or correlation between free
drug concentrations in plasma and in the infection site or the development of approaches
to restrict the selection of resistant mutants. Consequently, the strategies currently available
will change and more complex models with higher ability to predict clinical efficacy and/or
emergence of resistances will be developed and implemented.
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